Colon Cancer Clinical Trial
Official title:
Prognostic Molecular and Environmental Factors in High-Risk Stage II and Stage III Colon Cancer Patients
The goal of this research study is to identify biologic and lifestyle factors that may increase a person's risk of developing a recurrence (return) of colon cancer.
Treatment with drugs (chemotherapy) and frequent evaluations by a doctor are standard
practice to help prevent colon cancer from recurring after surgery. Despite these measures,
the cancer does recur in a significant number of people, usually within the first 2-3 years
from diagnosis.
In this study, researchers hope to identify genetic and environmental factors that may
contribute to a person developing recurrent colon cancer. To help identify these factors,
blood and tissue samples will be studied. You also will be asked to provide information about
your background, lifestyle, and eating habits.
Participants able to take part in this study have had all of their known colon cancer removed
by surgery and have agreed to receive chemotherapy to help prevent the cancer from recurring.
Before you take part in this study, your medical information will be reviewed, and a
performance status evaluation (how well you perform everyday activities) will be done. This
will help the doctor decide if you are eligible to take part in the study.
If you are found to be eligible and you agree to take part in the study, you will be asked to
fill out 2 questionnaires. One questionnaire asks about your background (age, education,
etc.), work history, any exposure to toxic substances, medical history, smoking and alcohol
history, family history of cancer, and your level of physical activity. The second
questionnaire contains questions about what types of foods you eat, how often you eat them,
whether you take vitamins and if so, what type(s). It will take about 30 minutes to fill out
both of these questionnaires.
If your surgery to remove your colon cancer was not performed at MD Anderson, you will not be
asked to participate in the tissue portion of this study described below but you will be
asked to participate in the blood sample analysis and the study evaluations and questionnaire
portion of this study every 3 months for a maximum of 2 years (starting from the beginning of
the follow-up period, once all treatment is complete) or until your disease returns, which
ever occurs first.
If your surgery was performed at MD Anderson Cancer Center, the samples of your cancer tissue
will be analyzed, looking for any biologic factors related to colon cancer. Blood samples
(about 4 teaspoons) for gene analysis (looking for any biologic factors associated with colon
cancer) will also be collected.
Once follow-up begins, you will have study evaluations at MD Anderson every 3 months for 2
years or until your disease returns, which ever occurs first. Blood samples (about 4
teaspoons) for gene analysis will be collected within 14 days of completion of chemotherapy,
and then every 3 months for 2 years after you enroll in this study. If your colon cancer
recurs, a blood sample will be taken at that time also.
You will be asked to fill out the 2 questionnaires described above at the completion of your
chemotherapy treatment (if applicable) and 1 and 2 years after your follow-up begins. If your
colon cancer recurs, you will be asked to fill out the questionnaires at that time.
If you require surgery for cancer after enrolling in this study, a sample of leftover tissue
will be collected for genetic analysis if the surgery is performed at MD Anderson Cancer
Center.
You will not be informed of any results of the analysis of your blood and tumor samples or
the questionnaires, as this research is exploratory. Your participation in this study will
end if your disease returns or 2 years after you begin, whichever occurs first.
This is an investigational study. Taking part in this study requires that you return
frequently to MD Anderson. Up to 200 participants will take part in this study. All will be
enrolled at MD Anderson.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT03457454 -
Reducing Rural Colon Cancer Disparities
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03390907 -
Hybrid APC Assisted EMR for Large Colon Polyps
|
N/A | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT04079478 -
The AID Study: Artificial Intelligence for Colorectal Adenoma Detection
|
||
Active, not recruiting |
NCT04057274 -
Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth
|
N/A | |
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05147545 -
Impact of Exercise and Hyperlipidic Meal on Free Circulating DNA in Patients With Metastatic Colonic Cancer and Healthy Subjects
|
N/A | |
Recruiting |
NCT05026268 -
The Laparoscopic Right Colectomy With Intracoroporeal Anastomosis
|
N/A | |
Not yet recruiting |
NCT03277235 -
Effect of a Resilience Model-Based Care Plan in Newly Diagnosed Colorectal Cancer Patients
|
N/A | |
Active, not recruiting |
NCT02730702 -
Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure
|
||
Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Recruiting |
NCT02526836 -
Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer
|
Phase 2/Phase 3 |